Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 20,435 | 2,722 | 2,423 | 1,556 | 1,075 |
| Cost of Goods | 9,328 | 1,603 | N/A | 4 | 8 |
| Gross Profit | 11,107 | 1,119 | 2,423 | 1,552 | 1,067 |
| Operating Expenses | 94,981 | 124,102 | 61,767 | 28,185 | 14,306 |
| Operating Income | -83,546 | -122,380 | -59,344 | -26,629 | -13,231 |
| Interest Expense | 10,660 | 7,163 | 2,545 | 2 | 2 |
| Other Income | 2,956 | 3,505 | 1,809 | 77 | 24 |
| Pre-tax Income | -91,250 | -126,038 | -60,080 | -26,554 | -13,209 |
| Income Tax | -110 | -458 | N/A | N/A | N/A |
| Net Income Continuous | -91,140 | -125,580 | -60,080 | -26,554 | -13,209 |
| Net Income | $-91,140 | $-125,580 | $-60,080 | $-26,554 | $-13,209 |
| EPS Basic Total Ops | -2.14 | -4.81 | -4.99 | -13.09 | -7.17 |
| EPS Basic Continuous Ops | -2.14 | -4.81 | -4.99 | -13.09 | -7.17 |
| EPS Diluted Total Ops | -2.14 | -4.81 | -4.99 | -13.09 | -7.17 |
| EPS Diluted Continuous Ops | -2.14 | -4.81 | -4.99 | -13.09 | -7.17 |
| EPS Diluted Before Non-Recurring Items | -2.14 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-81,099 | $-120,354 | $-58,464 | $-26,404 | $-13,115 |